Statins to treat chronic inflammation in dialysis patients - Is this feasible?

Peritoneal Dialysis International

Volumn 27, Issue 3, 2007, Pages 254-257

  Heimbürger, Olof ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ATORVASTATIN; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEASIBILITY STUDY; GENETIC POLYMORPHISM; HEART INFARCTION; HEMODIALYSIS; HUMAN; INCIDENCE; INSULIN RESISTANCE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MORTALITY; NOTE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PREDICTION; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; RISK FACTOR;

EID: 34447342803     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080702700308     Document Type: Note

References (31)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32(Suppl 5):S112-19.
2. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al. Atherosclerotic cardiovascular disease risks in chronic hemodial ysis patients. Kidney Int 2000; 58: 353-62.
3. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant of uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-38.
4. Stenvinkel P, Lindholm B, Heimbürger O. Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease. Semin Dial 2004; 17: 505-15.
5. Kumar S, Raftery M, Yaqoob M, Fan SLS. Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in peritoneal dialysis patients. Perit Dial Int 2007; 27:283-7.
6. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363-9.
7. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 1998; 18:387-94.
8. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin J-M. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002; 62: 1417-22.
9. Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, et al. Is a single time-point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2003; 14:1871-9.
10. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-26.
11. Stenvinkel P. C-reactive protein - does it promote vascular disease? Nephrol Dial Transplant 2006; 21:2718-20.
12. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits Filho R, Riella M, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 2005; 67:1216-33.
13. Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, Gaffney D, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 2006; 35:922-31.
14. Zhang L, Kao L, Berthier-Schaad Y, Plantinga L, Fink N, Smith MW, et al. C-reactive protein haplotype predicts serum C-reactive protein levels but not cardiovascular disease risk in a dialysis cohort. Am J Kidney Dis 2007; 49: 118-26.
15. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103:1933-5.
16. Albert MA, Danielsson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64-70.
17. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcome after statin therapy. N Engl J Med 2005; 352:20-8.
18. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tasi J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary heart disease. N Engl J Med 2005; 352:29-38.
19. März W, Winkler K, Nauck M, Böhm BO, Winkelmann BR. Effects of statins on C-reactive protein and interleukin-6 (The Ludwigshafen Risk and Cardiovascular Health Study). Am J Cardiol 2003; 92:305-8.
20. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002; 39:1213-17.
21. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 2004; 43:471-8.
22. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002; 17:1513-17.
23. Ikejiri A, Hirano T, Muryama S, Yoshino G, Gushiken N, Hyodo T, et al. Effects of atorvastatin on trig lyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 2004; 53:1113-17.
24. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients. Blood Coogul Fibrinolysis 2004; 15:463-7.
25. van der Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003; 16:238-44.
26. Tsirpanlis G, Boufidou F, Manganas S, Chantzis K, Bleta A, Stamatelou K, et al. Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients. Blood Purif 2004; 22:518-24.
27. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, et al. HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005; 45:119-26.
28. Tonelli M, Sacks FM, Kiberd B, Curhan GC. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138:98-104.
29. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110:1557-63.
30. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.
31. Carrero JJ, Axelsson J, Avesani C, Heimbürger O, Lindholm B, Stenvinkel P. Being an inflamed peritoneal dialysis patient - a Dante's journey. Contrib Nephrol 2006; 150: 144-51.